Sodium pentaborate pentahydrate

Preclinical

Sodium pentaborate pentahydrate is one of 3 therapeutic programs targeting Overweight and Obesity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight and ObesityCompleted

Overweight and ObesityPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Overweight and Obesity

#DrugCompanyPhaseTrials

AZD9550

AstraZeneca

Preclinical

1 2

LAE102 IV

LLaekna Limited

Phase 1

1 3

Sodium pentaborate pentahydrate

TTabriz University of Medical Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overweight and Obesity1 trial

Evaluation of the Safety and Efficacy and of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity: a Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial

Completed·TTabriz University of Medical Sciences·Preclinical·NCT05741606·177 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sodium pentaborate pentahydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sodium pentaborate pentahydrate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tabriz University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TTabriz University of Medical Sciences

Sodium pentaborate pentahydrate

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News